Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Use of Chemically Defined Media – V 2.0

Posted on By


Biosimilars: SOP for Use of Chemically Defined Media – V 2.0


Standard Operating Procedure for Use of Chemically Defined Media in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/063/2025
Supersedes SOP/BS/063/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the standardized procedure for selection, preparation, and use of chemically defined media (CDM) in upstream biosimilar manufacturing to ensure reproducibility, animal component-free operations, and alignment with regulatory expectations.

2. Scope

This SOP applies to all cell culture activities utilizing chemically defined media in biosimilar upstream processes including shake flasks, seed cultures, and bioreactors involving CHO, HEK293, and other mammalian cell lines.

3. Responsibilities

  • Process Technologist: Responsible for selecting and validating CDM for specific cell lines.
  • Upstream Operator: Prepares and handles CDM under aseptic conditions as per SOP.
  • QA: Reviews documentation and verifies traceability and batch records.

4. Accountability

The Head of Upstream Process is accountable for the implementation of CDM and ensuring batch-wise consistency and GMP-compliance in upstream cell culture operations.

5. Procedure

5.1 Media Selection and Validation

  1. Select CDM based on cell line compatibility and product titer objectives.
  2. Perform bench-scale studies comparing growth and productivity metrics in at least two media brands.
  3. Document comparative results in Media Evaluation Sheet (Annexure-1).

5.2 Preparation of CDM

  1. Confirm lot release and CoA of selected media powder or liquid formulation.
  2. Weigh and dissolve media in Water for Injection (WFI) using magnetic stirrers under cleanroom conditions.
  3. Adjust pH (6.8–7.2) using sterile NaOH or HCl if required.
  4. Filter through 0.22 µm sterile membrane filter into pre-labeled sterile vessels (Annexure-2).

5.3 Application in Cell Culture

  1. Thaw cryovial as per SOP/BS/027/2025 and initiate culture in T-flask with CDM.
  2. Monitor daily growth using VCD and viability via hemocytometer or cell counter.
  3. Scale up seed cultures in shake flasks maintaining optimal aeration and temperature (37°C, 5% CO₂).

5.4 Monitoring and Hold Time

  1. Check pH, osmolality, and sterility of CDM before each use.
  2. Store CDM at 2–8°C and use within validated hold time as per SOP/BS/099/2025.
  3. Dispose unused or expired media as per biosafety guidelines (SOP/BS/048/2025).

5.5 Documentation

  1. Record all preparation and usage in Media Usage Log (Annexure-3).
  2. Attach CoA, lot number, and QA release documents with batch record.

6. Abbreviations

  • CDM: Chemically Defined Media
  • WFI: Water for Injection
  • VCD: Viable Cell Density
  • GMP: Good Manufacturing Practice

7. Documents

  1. Media Evaluation Sheet – Annexure-1
  2. CDM Preparation and Label Record – Annexure-2
  3. Media Usage Log – Annexure-3

8. References

  • ICH Q5D – Derivation and Characterization of Cell Substrates
  • WHO TRS 999 – Biotechnological Manufacturing Practices
  • SOP/BS/099/2025 – Media Hold Time Validation

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Media Evaluation Sheet

Media Name Growth Rate Max VCD Product Titer Preferred?
CD CHO A 0.4/day 3.2 × 10⁶ 120 mg/L Yes
CD CHO B 0.3/day 2.8 × 10⁶ 95 mg/L No

Annexure-2: CDM Preparation and Label Record

Date Media Type Lot No. pH Filter ID Operator
03/05/2025 CD CHO A CC-A-0425 7.1 FT-022 Rajesh Kumar

Annexure-3: Media Usage Log

Date Batch ID Media Used Volume (L) Remarks
04/05/2025 SD-CHO-105 CD CHO A 5 Used for seed expansion

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Inclusion of osmolality checks and evaluation template Process Standardization
See also  Biosimilars: SOP for Restriction Enzyme Digestion and Mapping - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for Management of Trial Equipment Calibration Logs – V 2.0
Next Post: API Manufacturing: SOP for IPC Sign-Off on Batch Manufacturing Record – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version